Tataranu Ligia Gabriela, Turliuc Serban, Rizea Radu Eugen, Dricu Anica, Alexandru Oana, Staicu Georgiana-Adeline, Kamel Amira
Neurosurgical Department, University of Medicine and Pharmacy "Carol Davila", 020022 Bucharest, Romania.
Neurosurgical Department, Clinical Emergency Hospital "Bagdasar-Arseni", 041915 Bucharest, Romania.
Curr Issues Mol Biol. 2024 Jul 3;46(7):6903-6939. doi: 10.3390/cimb46070412.
Accounting for 48% of malignant brain tumors in adults, glioblastoma has been of great interest in the last decades, especially in the biomolecular and neurosurgical fields, due to its incurable nature and notable neurological morbidity. The major advancements in neurosurgical technologies have positively influenced the extent of safe tumoral resection, while the latest progress in the biomolecular field of GBM has uncovered new potential therapeutical targets. Although GBM currently has no curative therapy, recent progress has been made in the management of this disease, both from surgical and molecular perspectives. The main current therapeutic approach is multimodal and consists of neurosurgical intervention, radiotherapy, and chemotherapy, mostly with temozolomide. Although most patients will develop treatment resistance and tumor recurrence after surgical removal, biomolecular advancements regarding GBM have contributed to a better understanding of this pathology and its therapeutic management. Over the past few decades, specific biomarkers have been discovered that have helped predict prognosis and treatment responses and contributed to improvements in survival rates.
胶质母细胞瘤占成人恶性脑肿瘤的48%，在过去几十年中一直备受关注，特别是在生物分子和神经外科领域，因为其无法治愈的性质和显著的神经病理学特征。神经外科技术的重大进展对安全肿瘤切除范围产生了积极影响，而胶质母细胞瘤生物分子领域的最新进展揭示了新的潜在治疗靶点。尽管胶质母细胞瘤目前尚无治愈性疗法，但从手术和分子角度来看，在该疾病的管理方面最近都取得了进展。目前主要的治疗方法是多模式的，包括神经外科干预、放疗和化疗，主要使用替莫唑胺。尽管大多数患者在手术切除后会产生治疗抗性和肿瘤复发，但胶质母细胞瘤的生物分子进展有助于更好地理解这种病理学及其治疗管理。在过去几十年中，已经发现了特定的生物标志物，这些标志物有助于预测预后和治疗反应，并有助于提高生存率。
